A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations

Hua Ling, John T Luoma, Daniel Hilleman, Hua Ling, John T Luoma, Daniel Hilleman

Abstract

Fenofibrate is a third-generation fibric acid derivative indicated as a monotherapy to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B; to increase high-density lipoprotein cholesterol in patients with primary hyperlipidemia or mixed dyslipidemia; and to reduce triglycerides in patients with severe hypertriglyceridemia. In this review, the key characteristics of available fenofibrate formulations are examined. A literature search was conducted, focusing on comparative studies examining bioavailability, food effects, absorption, and lipid efficacy. Fenofibrate is highly lipophilic, virtually insoluble in water, and poorly absorbed. Coadministration with meals was necessary to maximize bioavailability of early formulations. Micronized and nanoparticle formulations of fenofibrate with reduced particle sizes were developed, resulting in greater solubility, improved bioavailability, and in some cases, the ability to be given irrespective of food. A recently introduced hydrophilic choline salt of fenofibric acid also can be taken without regard to meals, is absorbed throughout the gastrointestinal tract, has the highest bioavailability among marketed formulations, and is approved for coadministration with a statin. Differences in bioavailability of fenofibrate formulations have resulted in low-dose (40 - 67) mg and standard-dose (120 - 200 mg) formulations. Different formulations are not equivalent on a milligram-to-milligram basis. In order to prevent medication errors, resulting in underdosing or overdosing with attendant consequences, it is important for healthcare providers to recognize that the formulations of fenofibrate and fenofibric acid that are currently available vary substantially in relation to food effect, equivalency on a milligram-to-milligram basis, and indication to be coadministered with a statin.

Keywords: Bioavailability; Fenofibrate; Fenofibric acid; Formulation; Mixed dyslipidemia; Triglycerides.

Figures

Figure 1
Figure 1
(a) Chemical structure of fenofibrate and fenofibric acid; (b) Comparison of fenofibrate formulations.

References

    1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM. et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25–146. doi: 10.1161/CIRCULATIONAHA.107.187998.
    1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
    1. Toth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol. 2012;6(4):325–330. doi: 10.1016/j.jacl.2012.05.002.
    1. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239. doi: 10.1161/01.CIR.0000133317.49796.0E.
    1. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78(6):393–403. doi: 10.3949/ccjm.78a.10073.
    1. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC. et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96(4):556–563. doi: 10.1016/j.amjcard.2005.04.019.
    1. DeGuzman PB, Akosah KO, Simpson AG, Barbieri KE, Megginson GC, Goldberg RI, Beller GA. Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies. Diab Vasc Dis Res. 2012;9(2):138–145. doi: 10.1177/1479164111431471.
    1. Saurav A, Kaushik M, Mohiuddin SM. Fenofibric acid for hyperlipidemia. Expert Opin Pharmacother. 2012;13(5):717–722. doi: 10.1517/14656566.2012.658774.
    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278. doi: 10.1016/S0140-6736(05)67394-1.
    1. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J. et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–125. doi: 10.1016/S0140-6736(08)60104-X.
    1. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ. et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(10 Suppl):1K–34K. doi: 10.1016/j.amjcard.2008.10.002.
    1. Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12(12):1945–1958. doi: 10.1517/14656566.2011.593509.
    1. Schima SM, Maciejewski SR, Hilleman DE, Williams MA, Mohiuddin SM. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert Opin Pharmacother. 2010;11(5):731–738. doi: 10.1517/14656560903575639.
    1. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007;67(1):121–153. doi: 10.2165/00003495-200767010-00013.
    1. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088–2093. doi: 10.1161/01.CIR.98.19.2088.
    1. Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1997;54(4):615–633. doi: 10.2165/00003495-199754040-00007.
    1. Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur J Pharm Biopharm. 2008;68(2):283–288. doi: 10.1016/j.ejpb.2007.05.010.
    1. Bosselmann S, Williams RO. Has nanotechnology led to improved therapeutic outcomes? Drug Dev Ind Pharm. 2012;38(2):158–170. doi: 10.3109/03639045.2011.597764.
    1. Rawat N, Kumar SM, Mahadevan N. Solubility: particle size reduction is a promising approach to improve the bioavailability of lipophillic drugs. Int J Recent Adv Pharm Res. 2011;1:8–18.
    1. Guichard JP, Blouquin P, Qing Y. A new formulation of fenofibrate: suprabioavailable tablets. Curr Med Res Opin. 2000;16(2):134–138.
    1. Guivarc'h PH, Vachon MG, Fordyce D. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. Clin Ther. 2004;26(9):1456–1469. doi: 10.1016/j.clinthera.2004.09.015.
    1. Trilipix® (fenofibric acid delayed release capsules). Full Prescribing Information, Abbott Laboratories, North Chicago, IL, 2011.
    1. Lofibra® (fenofibrate tablets). Full Prescribing Information, Gate Pharmaceuticals, Sellersville, PA, 2010.
    1. Lipofen® (fenofibrate). Full Prescribing Information, Galephar Pharmaceutical Research, Juncos, PR, 2007.
    1. Fenoglide (fenofibrate). Full Prescribing Information, Sciele Pharma, Atlanta, GA, 2009.
    1. Lofibra® (fenofibrate capsules). Full Prescribing Information, Gate Pharmaceuticals, Sellersville, PA, 2003.
    1. Triglide® (fenofibrate). Full Prescribing Information, Sciele Pharma, Atlanta, GA, 2007.
    1. Tricor® (fenofibrate). Full Prescribing Information, Abbott Laboratories, Chicago, IL, 2004.
    1. Antara® (fenofibrate). Full Prescribing Information, Oscient Pharmaceuticals Corporation, Emeryville, CA, 2006.
    1. Fenofibrate (generic). Full Prescribing Information, Global Pharmaceuticals, Philadelphia, PA, 2011.
    1. Fenofibrate (generic). Full Prescribing Information, Mylan Pharmaceuticals Inc, Morgantown, WV, 2010.
    1. Fenofibrate (generic). Full Prescribing Information, Ranbaxy Pharmaceuticals Inc, Jacksonville, FL, 2009.
    1. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861. doi: 10.1016/S0140-6736(05)67667-2.
    1. Micronized-Fenofibrate (generic). Full Prescribing Information, Global Pharmaceuticals, Philadelphia, PA, 2009.
    1. Tricor® (fenofibrate). Full Prescribing Information, Abbott Laboratories, Chicago, IL, 2011.
    1. Sauron R, Wilkins M, Jessent V, Dubois A, Maillot C, Weil A. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int J Clin Pharmacol Ther. 2006;44(2):64–70.
    1. Armenti JBV. 2nd ed ed. New York, NY: Human Press; 2010. Handbook of Drug-Nutrient Interactions.
    1. Sonet B, Vanderbist F, Streel B, Houin G. Randomised crossover studies of the bioequivalence of two fenofibrate formulations after administration of a single oral dose in healthy volunteers. Arzneimittelforschung. 2002;52(3):200–204.
    1. Vlase L, Popa A, Muntean D, Leucuta SE. Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers. Arzneimittelforschung. 2010;60(9):560–563.
    1. Zhu T, Ansquer JC, Kelly MT, Sleep DJ, Pradhan RS. Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans. J Clin Pharmacol. 2010;50(8):914–921. doi: 10.1177/0091270009354995.
    1. Godfrey AR, Digiacinto J, Davis MW. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials. Clin Ther. 2011;33(6):766–775. doi: 10.1016/j.clinthera.2011.05.047.
    1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001;285(19):2486–2497. doi: 10.1001/jama.285.19.2486.
    1. Davidson MH, Jones PH. Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. Clin Drug Investig. 2008;28(10):615–623. doi: 10.2165/00044011-200828100-00002.
    1. Maciejewski S, Hilleman D. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. Pharmacotherapy. 2008;28(5):570–575. doi: 10.1592/phco.28.5.570.
    1. Davidson MH, Bays H, Rhyne J, Stein E, Rotenberg K, Doyle R. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2005;27(6):715–727. doi: 10.1016/j.clinthera.2005.06.017.
    1. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT. et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574. doi: 10.1056/NEJMoa1001282.
    1. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25(7):1198–1202. doi: 10.2337/diacare.25.7.1198.
    1. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract. 2004;64(2):137–151. doi: 10.1016/j.diabres.2003.11.012.
    1. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi IS. et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. 2005;45(10):1649–1653. doi: 10.1016/j.jacc.2005.02.052.
    1. Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze CM, Buttler SM. et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008;2(6):426–435. doi: 10.1016/j.jacl.2008.10.001.
    1. Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ. et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009;103(4):515–522. doi: 10.1016/j.amjcard.2008.10.025.
    1. Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ. et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 2009;204(1):208–215. doi: 10.1016/j.atherosclerosis.2008.09.027.
    1. Mohiuddin SM, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009;157(1):195–203. doi: 10.1016/j.ahj.2008.08.027.
    1. Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS. et al. A phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia. J Am Coll Cardiol. 2009;53(suppl A):A208.
    1. Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS. et al. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovasc Drugs Ther. 2010;24(5-6):421–428. doi: 10.1007/s10557-010-6266-4.
    1. Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ. et al. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Clin Drug Investig. 2010;30(1):51–61. doi: 10.2165/11319800-000000000-00000.
    1. Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2011;25(1):47–57. doi: 10.1007/s10557-010-6273-5.
    1. Ballantyne CM, Jones PH, Kelly MT, Setze CM, Lele A, Thakker KM, Stolzenbach JC. Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovasc Drugs Ther. 2011;25(1):59–67. doi: 10.1007/s10557-011-6280-1.
    1. Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009;31(12):2824–2838. doi: 10.1016/j.clinthera.2009.12.007.
    1. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692–694. doi: 10.1056/NEJMc1006407. author reply 694-695.
    1. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE. et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875–1884. doi: 10.1016/S0140-6736(10)60656-3.
    1. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011;57(2):267–272. doi: 10.1097/FJC.0b013e318202709f.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa